OXiGENE Announces Third Quarter 2009 Earnings Conference Call and Webcast

• Press Release
• Source: OXiGENE, Inc.
• On 2:00 am EST, Tuesday November 3, 2009

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News) (Stockholm:OXGN - News), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report third quarter 2009 results on Monday, November 9th, 2009. A conference call and webcast hosted by OXiGENE management will begin at 9:00 a.m. EST (6:00 a.m. PST).

Related Quotes

Symbol	Price	Change
OXGN	1.25	0.00

{"s" : "oxgn,oxgn.st","k" : "c10,l10,p20,t10","o" : "","j" : ""}

To listen to a live or archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investor" tab, select the link to "Events and Presentations".

OXiGENE's earnings conference call can also be heard live by dialing 888-504-7949 in the United States and Canada, and 719-325-2215 for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 12:00 p.m., EST (9:00 a.m., PST) on November 3, 2009 and ending at 12:00 midnight EST (9:00 p.m., PST) on Monday, November 23rd, 2009. To access the replay, please dial (888) 203-1112 if calling from the United States or Canada, or (719) 457-0820 from international locations. Please refer to replay pass code 4502965.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
medwards@oxigene.com